Overview

Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the study is to evaluate the event free survival at three years in patients with diffuse large B-cell lymphoma with poor prognostic factors receiving R-MegaCHOP as induction therapy. Patients with positive PET after three cycles of R-MegaCHOP receive early salvage treatment with R-IFE and autologous stem cell transplantation. Patients with negative PET after three cycles of R-MegaCHOP are treated with three additional cycles of R-MegaCHOP without transplant.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Criteria
Inclusion Criteria:

1. follicular lymphoma grade III diagnosed patients, diffuse large B-cell lymphoma,
histologically confirmed with CD20+

2. aged between 18 and 65 years. Patients aged from 65 to 70 years can be included
according to the investigator's criteria regarding the patients' global health status
and the absence of excluding comorbidity.

3. IPI adjusted to the age over 1 or a-IPI and beta2-microglobulin equal or higher than 3
mg/dl 3. Punctuation in the ECOG grade from 0 to 4

4. Life expectancy over 12 weeks

5. Written informed consent form 6. New diagnosed patient without any previous treatment

Exclusion Criteria:

1. Existence of severe cardiac, pulmonary, neurologic, psychiatric and metabolic diseases
not caused by the lymphoma.

2. uncontrolled high blood pressure (diastolic pressure in rest > 115 mmHg)

3. Altered hepatic function (bilirubin or AST/ALT superior or equal at 2 times the
superior limit of normality) or renal (creatinine equal or superior at 1.5 times the
superior limit of normality) not caused by the lymphoma.

4. other malignant neoplasias along the past 5 years, except skin tumors, excluded
melanoma or carcinoma in situ of cervix

5. patients positive for HIV

6. patients with transformed follicular lymphoma

7. pregnant women or in nursing; women of childbearing age who do not use an adequate
contraceptive method before being included in the study

8. ventricular ejection fraction inferior to 50%

9. patients with severe psychiatric diseases which can interfere with their ability for
understanding the study (including alcoholism or drug addiction)